COMPETITIVE MOLECULE NOTE | INDIA | AMOXICILLIN-CLAVULANATE

Pharma

MOLECULE AND FORMULATION MARKETING PLAYBOOK

THE NEXT SHARE SHIFT IN AMOX-CLAV WILL NOT COME FROM MORE ANTIBIOTIC NOISE

A CLINIC-CENTRED STEWARDSHIP AND GROWTH PLAYBOOK FOR BRANDS DEFENDING LEADERSHIP, ATTACKING LEADERSHIP, OR TAKING SELECTIVE SHARE

THIS PUBLICATION IS BEING CIRCULATED ACROSS THE LEADERSHIP TEAMS OF COMPETING AMOXICILLIN-CLAVULANATE BRANDS IN INDIA. BRANDS WISHING TO IMPLEMENT THIS SOLUTION MAY WRITE TO :

AMIT@INDITECH.CO.IN

THE NEXT SHARE SHIFT IN AMOXICILLIN-CLAVULANATE

Amoxicillin-clavulanate is one of India's most commercially visible antibiotic molecules. Public market reporting shows the scale of the category: Augmentin was reported as a long-established market leader with ₹80 crore sales in October 2025, while Reuters separately reported that GSK India's performance benefited from rising market share and sustained demand for Augmentin. (The Times of India) (Reuters)

But the molecule now sits inside a different climate. Antimicrobial resistance is one of the top global public-health threats; WHO states that misuse and overuse of antimicrobials are major drivers of resistance, and its AWaRe antibiotic book exists precisely to support evidence-based antibiotic choice, dose, route, and duration for common infections. (World Health Organization) (World Health Organization)

That changes the commercial game. The next winner in amoxicillin-clavulanate will not be the brand that shouts "broad spectrum" louder. It will be the brand that first becomes the clinic's trusted system for: right patient, right prescription, right completion, right review.

This publication outlines a molecule-specific clinic workflow model for amoxicillin-clavulanate. It is built for three strategic positions: brands defending leadership, brands trying to displace the leader, and brands seeking selective market-share gain. It is being shared across major competing amox-clav brand teams because the opportunity is molecule-wide, not brand-specific.

The question is not whether amox-clav will remain a large market. The question is which brand will own responsible use before the rest of the market is forced to imitate.

EXECUTIVE SUMMARY

Amoxicillin-clavulanate is commercially powerful but strategically exposed.

For years, the molecule has benefited from a simple market reality: doctors know it, patients recognize it, chemists stock it, and brands keep fighting for recall. But that same familiarity has created a dangerous trap.

The market has become too easy. Too many prescriptions are treated as routine. Too many patients remember only "antibiotic," not the brand. Too much post-visit behaviour is invisible. Too many incomplete courses, substitutions, repeat self-use episodes, and poor follow-ups happen outside the clinic's control.

That is where brand value leaks.

For amox-clav, the commercial breakpoints are not only at the moment of prescription. They sit across the whole infection-care journey:

diagnostic sorting → antibiotic decision → brand choice → dispensing → course completion → response review → recurrence / non-response management

Most brands still compete mainly at one point: the prescription desk. That is no longer enough.

The new commercial battleground is clinic-controlled antibiotic workflow.

The new competition is about controlling how antibiotics are used in clinics.

The brand that installs this workflow first gains a defensible advantage: doctor trust, patient continuity, reduced substitution leakage, measurable engagement, and a stronger claim to responsible antibiotic stewardship.

In this molecule, stewardship is not a defensive CSR layer. It is the next brand weapon.

“DIAGNOSTIC SORTING → ANTIBIOTIC DECISION → BRAND CHOICE → DISPENSING → COURSE COMPLETION → RESPONSE REVIEW → RECURRENCE / NON-RESPONSE MANAGEMENT”

MARKET REALITY

THE GUIDELINE – REALITY GAP

Amoxicillin-clavulanate is not a small, specialist, hard-to-explain molecule. It is a large, familiar, high-frequency antibiotic space. That creates scale, but it also creates commoditisation.

The category has four hard realities.

First, the molecule is widely trusted.
That is good for volume, but bad for brand differentiation. When the molecule is accepted, the brand decision becomes fast, habitual, and substitutable.

Second, the brand set is crowded.
The market has entrenched leaders, aggressive challengers, and a long tail of brands competing for the same prescription moment.

Third, patient behaviour is poorly controlled after the prescription.
The patient may delay starting, miss doses, stop early, switch brands, ask the chemist for an alternative, or reuse an old strip later.

Fourth, the stewardship climate has changed.
Any antibiotic brand that looks like it is simply pushing more consumption will increasingly lose credibility with better doctors.

That is the opening. A brand can now win by doing what the rest of the category has failed to do: make responsible antibiotic use operational inside the clinic.

"MAKE RESPONSIBLE ANTIBIOTIC USE OPERATIONAL INSIDE THE CLINIC."

THE DRIFT DEFINITION

The drift in amoxicillin-clavulanate is not that doctors do not know the molecule.

The drift is that, once the doctor decides an antibiotic is needed, the market loses control of what happens next.

The pattern is familiar:

infection complaint → fast antibiotic decision → brand written → chemist substitution risk → patient confusion → incomplete course → no structured review → repeat episode → fresh brand decision

This creates five types of leakage.

1. Brand leakage
The doctor writes one brand. The patient receives another. The brand loses the transaction even when it won the prescription.

2. Completion leakage
The patient improves and stops early, forgets doses, or stretches the course incorrectly. The clinic does not know.



3. Review leakage
The patient is not better, but instead of returning to the doctor, they ask the chemist, change medicine, add medicines, or wait too long.

4. Trust leakage
Doctors become more cautious about antibiotic promotion because most brand inputs do not help them solve the stewardship problem.

5. Re-entry leakage
The next infection episode begins the game again. The brand has not built memory, continuity, or clinic infrastructure.

So the molecule remains commercially large but behaviourally loose.

That is the drift this playbook attacks.

"INFECTION COMPLAINT → FAST ANTIBIOTIC DECISION → BRAND WRITTEN → CHEMIST SUBSTITUTION RISK → PATIENT CONFUSION → INCOMPLETE COURSE → NO STRUCTURED REVIEW → REPEAT EPISODE → FRESH BRAND DECISION"

PROBLEM FRAMEWORK

MOST AMOX-CLAV BRANDS ARE STILL SELLING THE MOLECULE. THE NEXT WINNER WILL SELL CONTROL.

In a crowded antibiotic market, "more reminder frequency" is not strategy. It is maintenance.

The deeper problem is that most brands are still operating inside the old playbook:

- remind doctors of the molecule
- push perceived strength
- compete on brand recall
- defend availability
- depend on field force repetition
- accept post-prescription leakage as unavoidable

This approach made sense when the market was less crowded and stewardship pressure was lower. It now creates vulnerability.

The most credible doctors do not need another antibiotic slogan. They need help with the practical frictions around antibiotic use:

- Which patients should come back if fever persists?
- How do we reduce self-medication and repeat use?
- How do we improve course completion?
- How do we stop chemist-led substitution?
- How do we make sure the patient does not disappear after partial response?
- How do we reinforce correct use without adding clinic workload?

THAT IS WHERE AN AMOX-CLAV BRAND CAN BECOME MORE THAN A PRODUCT. IT CAN BECOME A CLINIC UTILITY.

THE BEHAVIOURAL MOMENT MAP

AMOXICILLIN-CLAVULANATE SHARE IS WON OR LOST ACROSS SEVEN MOMENTS.

MOMENT 1: SYMPTOM START

The patient presents with fever, sore throat, cough, sinus symptoms, ear pain, dental pain, skin infection, urinary symptoms, or another infection-like complaint.

Before the doctor is involved, the patient may already have a mental model:
“I need an antibiotic.”
“Last time this worked.”
“The chemist will give something.”
“I have half a strip at home.”

At this moment, the category is active, but the clinic is not yet in control.



MOMENT 2: CLINICAL SORTING

This is the most important stewardship moment. The doctor decides whether the presentation is likely bacterial, viral, self-limiting, complicated, severe, recurrent, or in need of investigation / referral.

This is where a responsible brand must behave differently.

The brand should not try to convert every infection complaint into amox-clav use. It should help the doctor reinforce correct sorting. That earns trust.

MOMENT 3: ANTIBIOTIC DECISION

If an antibiotic is clinically justified, the doctor chooses the class and molecule.

At this point, amox-clav may be appropriate in selected situations, depending on the doctor’s clinical judgment, local practice, guidelines, and patient profile.

The brand opportunity begins only after this decision is made.

MOMENT 4: BRAND CHOICE

The doctor writes the brand. This moment is fast. Habit dominates. Brand recall matters, but workflow presence matters more.

The brand that sits inside the doctor's stewardship workflow has a stronger claim than the brand that simply appears in a reminder visual.

MOMENT 5: DISPENSING

The patient reaches the pharmacy. This is where many brands lose despite winning the doctor. Substitution, availability, price comparison, and chemist habit can quietly break prescription intent.

The clinic needs a simple way to tell the patient: Take exactly what your doctor prescribed. Do not change the medicine without asking the clinic.

That message must come from the clinic, not from the brand.

MOMENT 6: 48–72 HOUR RESPONSE

This is the key post-prescription moment. The patient may be improving, not improving, worsening, missing doses, experiencing intolerance, or confused about what to do next.

Most brands are absent here. A clinic-owned response check makes the doctor look more responsible and the sponsoring brand more useful.



MOMENT 7: COURSE COMPLETION AND RE-ENTRY

The patient finishes, stops early, stores leftovers, shares tablets, or repeats the antibiotic later without review.

This is where the stewardship battle is either won or lost. The brand that helps clinics reduce this behaviour earns a different type of loyalty.

Not promotional loyalty. Operational loyalty.

THE CLINIC-CENTRED SOLUTION FRAMEWORK

RIGHT START. RIGHT FINISH. RIGHT REVIEW.

A CLINIC-CENTRED ANTIBIOTIC STEWARDSHIP WORKFLOW FOR AMOXICILLIN-CLAVULANATE

The objective is not to increase indiscriminate antibiotic use. The objective is to make the sponsoring brand the doctor's preferred amox-clav brand when amox-clav is clinically justified, by helping the clinic control the patient journey before and after the prescription.

The system has three promises:

- **RIGHT START**

Help the doctor reinforce appropriate antibiotic use and reduce casual, patient-driven antibiotic demand.

- **RIGHT FINISH**

Help the patient complete the prescribed course correctly and avoid unsupervised switching or early stopping.

- **RIGHT REVIEW**

Help the clinic identify non-response, recurrence, adverse signals, or inappropriate repeat use. This is not an awareness campaign. It is an antibiotic control system.

THE SERVICE ARCHITECTURE



MODULE 1: Clinic-branded Infection Care Link

A clinic-branded digital link shared by clinic staff through QR code, WhatsApp, or printed card.

This link is patient-facing, but not promotional.

- It does not show the pharma brand.
- It does not recommend antibiotics.
- It does not allow patient self-diagnosis.
- It does not tell patients to start, stop, or change antibiotics.

It does four things only:

1. explains how to follow the doctor's prescription
2. reminds the patient not to change or reuse antibiotics without medical advice
3. collects simple response signals at defined time points
4. prompts return-to-clinic when needed

The patient experience is simple, multilingual, and clinic-branded.

Suggested name: My Clinic Infection Care Check, or Doctor's Infection Follow-up Link

The name must sound like clinic care, not brand marketing.

MODULE 2: Doctor-facing Antibiotic Decision Cue

This is an academy-backed doctor-facing tool.

It should be used during field visits and left behind as a small clinical utility, not as a sales leaflet.

The cue should reinforce:

- when antibiotic use should be considered
- when watchful waiting or symptomatic care may be more appropriate
- when red flags require review or escalation
- why course completion and follow-up matter
- why patient-led reuse is risky
- why substitution should be avoided without doctor consent

The sponsoring brand appears only in the doctor-facing execution layer, not in the patient education layer.

The brand role is: "When you decide amox-clav is appropriate, this brand helps your clinic control the complete antibiotic journey."

That is the core line.



MODULE 3: Prescription Protection Message

The goal is to reduce brand leakage after the patient leaves the clinic.

This cannot be done through crude patient-facing brand promotion. It should be done through clinic authority.

The clinic-branded message can say: Please take the medicine exactly as prescribed by your doctor. Do not change the brand, dose, frequency, or duration without checking with the clinic.

This protects the doctor's prescription intent. It also protects the brand, without making the patient-facing tool look promotional.

"THE OBJECTIVE IS TO MAKE THE SPONSORING BRAND THE DOCTOR'S PREFERRED AMOX-CLAV BRAND WHEN AMOX-CLAV IS CLINICALLY JUSTIFIED, BY HELPING THE CLINIC CONTROL THE PATIENT JOURNEY BEFORE AND AFTER THE PRESCRIPTION."

MODULE 4: 48–72 Hour Response Check

A simple clinic-branded follow-up check is sent after the prescription.

It asks:

- Are symptoms improving?
- Is fever continuing?
- Have any symptoms worsened?
- Has the patient missed doses?
- Has the medicine been changed at the pharmacy?
- Is there vomiting, rash, breathing difficulty, severe diarrhoea, or another concerning symptom?
- Does the patient need a clinic review?

No medical decision is automated. The system only flags the clinic.

This creates a powerful doctor benefit: the clinic no longer loses sight of infection patients after writing the antibiotic.

MODULE 5: Course Completion Check

At the end of the prescribed course, the patient receives a clinic-branded completion check.

It reinforces:

- complete only as prescribed
- do not save leftovers for future illness
- do not share antibiotics
- return to clinic if symptoms persist or recur
- do not restart antibiotics without medical advice

This is where the brand earns stewardship credibility.

Most antibiotic brands talk about efficacy. This brand helps the clinic prevent bad antibiotic behaviour. That is much harder to copy.

MODULE 6: Recurrence and Reuse Prevention Loop

For repeat infection-like complaints, the same clinic link can ask:

- Is this a new episode?
- Was an antibiotic taken recently?
- Was it prescribed or self-started?
- Was the previous course completed?
- Is this the same symptom returning?
- Has the patient used leftover medicines?

This helps the clinic regain control before the patient returns to self-medication or pharmacy-led antibiotic cycling.

The system converts repeat infection behaviour into a clinic re-entry moment. That is commercially valuable and clinically responsible.

DOCTOR EDUCATION INFRASTRUCTURE

The academic layer is what makes the whole model credible.

For amoxicillin-clavulanate, the education cannot look like old antibiotic promotion. It must be sharper, more responsible, and more useful.

Suggested six-month academy-backed education sequence

Month 1
The antibiotic decision is not the end of care - it is the start of responsibility,

Core message: once an antibiotic is prescribed, the clinic must still control dispensing, adherence, response, and review.

Month 2
When patients demand antibiotics: practical language for saying yes, no, or review,

Core message: doctors need patient-facing scripts that preserve authority without overprescribing.

Month 3
The 48–72 hour infection checkpoint: when improvement, non-response, or worsening should trigger action,

Core message: the most important post-antibiotic moment is usually invisible unless the clinic creates a check.

Month 4
Course completion and leftover antibiotics: the silent drivers of repeat misuse,

Core message: patient behaviour after symptom improvement is a major leak point.

“EACH MODULE SHOULD BE SHORT. ONE PAGE. DOCTOR-FACING. ENGLISH. ACADEMY-BACKED. FIELD-REP DELIVERABLE IN UNDER FIVE MINUTES. THIS IS NOT A CME LIBRARY. IT IS A BEHAVIOUR-SHAPING SYSTEM.”

Month 5

Prescription substitution: why the medicine written by the doctor should not be casually changed,

Core message: substitution is not only a commercial problem; it can confuse adherence and accountability.

Month 6

Building a clinic-level antibiotic stewardship routine without slowing practice,

Core message: stewardship must be operational, not theoretical.

Each module should be short. One page. Doctor-facing. English. Academy-backed. Field-rep deliverable in under five minutes. This is not a CME library. It is a behaviour-shaping system.



THE BRAND ROLE

WHERE THE SPONSORING BRAND APPEARS

The brand should appear only where it is legitimate and useful:

- doctor-facing decision cue
- doctor-facing monthly education material
- field-rep installation conversation
- brand dashboard for internal performance measurement
- prescription execution layer after the doctor has chosen amox-clav

The brand should not appear in:

- patient symptom education
- patient follow-up screens
- red-flag guidance
- adherence reminders
- clinic-branded WhatsApp messages
- any message that could be interpreted as patient-directed antibiotic promotion

This separation is important. It allows the doctor to trust the service. It allows the clinic to use it. It allows the brand to underwrite the system without looking like it is pushing antibiotics to patients.

STRATEGIC VARIANTS BY BRAND POSITION

IF YOU ARE THE LEADER

DEFEND THE DEFAULT BEFORE STEWARDSHIP BECOMES SOMEONE ELSE'S WEAPON

Your current advantage is habit. That is useful but vulnerable.

If a challenger becomes the first amox-clav brand to install a serious clinic-level antibiotic stewardship workflow, your leadership starts to look old-fashioned. The challenger will not need to outspend you everywhere.

It will reframe the category around responsible use and clinic control. Your risk is not that doctors forget you. Your risk is that doctors begin to see another brand as more useful.

Your play:

- occupy the stewardship system first
- become the clinic's responsible amox-clav default
- reduce prescription-to-dispensing leakage
- create follow-up visibility after the prescription
- make competing brands look like conventional antibiotic reminders

The leader's strongest move is to turn scale into infrastructure. Do not wait for a challenger to make responsibility their attack narrative.

IF YOU ARE THE CHALLENGER

The leader owns memory. You can own the new behaviour.

A challenger brand should not try to beat the leader by saying the same things more loudly. It should attack the category's weak point: the leader may be recalled, but it may not own the clinic workflow.

Your play:

- install the stewardship system in selected clinics
- become the brand associated with completion, review, and responsible use
- show doctors you are not just asking for prescriptions; you are reducing their infection-care burden
- convert clinic trust into repeat brand preference

The challenger's strongest line is: "When you decide amox-clav is appropriate, our brand helps your clinic ensure the prescription is completed, reviewed, and protected."

That is a different conversation. It moves the brand from memory to utility.

DO NOT OUTSHOUT THE LEADER. MAKE THE LEADER LOOK LIKE THE OLD ANTIBIOTIC PLAYBOOK.



IF YOU ARE A SHARE-GAIN BRAND

DO NOT TRY TO WIN THE WHOLE MOLECULE. OWN A HIGH-VALUE WEDGE.

A mid-tier or regional amox-clav brand should not start by trying to defeat national leaders across all prescribers.

That is expensive and unfocused.

Instead, select one defensible wedge:
- high-volume GP clinics
- ENT-heavy practices
- dental infection clusters
- paediatric-heavy family clinics
- semi-urban prescription markets
- high-substitution pharmacy areas
- clinics with frequent repeat infection visits
- geographies where field access is strong

Your play:
- choose 100–300 clinics
- install the infection follow-up system
- create doctor dependence on the workflow
- measure brand-of-use movement
- expand only after the wedge proves repeatability

The goal is not broad awareness. The goal is local workflow control.



FIELD FORCE STORYLINE

THE REP CONVERSATION SHOULD CHANGE COMPLETELY.

The old call says:
“Doctor, please prescribe our amox-clav brand.”

The new call says:
“Doctor, amox-clav prescriptions do not end at the prescription desk. Patients switch, stop early, reuse, and fail to come back when they should. We have built a clinic-branded infection follow-up system that helps your clinic control the full antibiotic journey. When you decide amox-clav is appropriate, our brand supports the responsible-use workflow around that decision.”

This is a much stronger call. It gives the doctor something operational. It gives the rep a reason to return monthly. It gives the brand a service asset competitors cannot neutralize with another reminder card.

IMPLEMENTATION MODULES

PHASE 1: MOLECULE DIAGNOSTIC



Identify the highest-value use-contexts for the brand:

- GP
- ENT
- dental
- paediatric family practice
- dermatology / skin infection
- mixed urban family clinics
- semi-urban high-volume clinics

Then classify each target group by likely leakage:

- substitution-heavy
- incomplete-course-heavy
- repeat-infection-heavy
- high patient-demand pressure
- poor review compliance
- high chemist influence

PHASE 2: CLINIC INSTALLATION

For each clinic:

- capture clinic name, logo, languages, and preferred contact method
- generate clinic-branded Infection Care Link
- train clinic staff to share QR / WhatsApp link
- give doctor the decision cue and patient script
- create simple reporting access for clinic / field team

PHASE 3: FIRST PRESCRIPTION WORKFLOW

When the doctor prescribes an antibiotic, the clinic shares the link.

The link reinforces:

- take only as prescribed
- do not substitute without clinic advice
- do not stop early without doctor instruction
- complete follow-up check
- contact clinic for red flags or non-response

PHASE 4: RESPONSE CHECK

At 48–72 hours, the system collects response signals. The clinic sees only meaningful alerts. This keeps workload manageable.

PHASE 5: COMPLETION CHECK

At the end of the prescribed course, the system reinforces completion and prevents leftover / repeat misuse behaviour.

PHASE 6: MONTHLY ACADEMIC REINFORCEMENT

Each month, field reps return with one academy-backed micro-topic. The system becomes a habit. Not a campaign burst.

MEASUREMENT LOGIC

THE MEASUREMENT SYSTEM MUST PROVE TWO THINGS:



1. The clinic is using the workflow.
2. The brand is gaining controlled share where the workflow is active.



CLINIC ACTIVATION METRICS

- clinics onboarded
- active clinics per week
- number of Infection Care Links shared
- repeat usage by clinic
- staff participation rate

PATIENT WORKFLOW METRICS

- link opens
- 48–72 hour check completions
- course-completion check completions
- non-response flags
- missed-dose signals
- substitution signals
- recurrence / reuse signals

DOCTOR ENGAGEMENT METRICS

- monthly education module opens
- doctor discussion rate
- repeat use of decision cue
- clinic staff adoption
- doctor willingness to continue system

BRAND OUTCOME PROXIES

- brand-of-use in activated clinics
- prescription-to-dispensing retention proxy
- same-brand repeat prescription rate
- share change versus matched control clinics
- incremental sales in active clinic clusters
- reduced substitution leakage signals

STEWARDSHIP CREDIBILITY METRICS

- patient education completion
- reduction in self-reported leftover use
- increase in clinic re-entry for non-response
- increase in correct follow-up behaviour
- doctor perception of brand as responsible-use partner



THE STRONGEST DASHBOARD IS NOT JUST "MORE PRESCRIPTIONS." IT IS: MORE APPROPRIATE CLINIC CONTROL AROUND PRESCRIPTIONS THAT WERE ALREADY CLINICALLY JUSTIFIED.

THAT IS THE DEFENSIBLE CLAIM.

COMPLIANCE AND TRUST GUARDRAILS



The following rules becomes non-negotiable.

PATIENT-FACING LAYER

- no brand name
- no molecule promotion
- no antibiotic recommendation
- no self-diagnosis
- no instruction to start, stop, change, or repeat antibiotics
- no dosage guidance unless entered by the doctor / clinic
- no claim that antibiotics are needed for fever, cough, cold, sore throat, or infection symptoms in general

DOCTOR-FACING LAYER

- academy-backed
- evidence-aligned
- focused on appropriate use
- clear that clinical judgment governs all decisions
- brand appears only after the doctor has chosen amox-clav as appropriate

COMMERCIAL LAYER

- no incentive linked to inappropriate prescribing
- no suggestion that the system exists to increase antibiotic use
- no pressure messaging to patients
- no pharmacy-facing substitution games that undermine clinical accountability

The strategic principle is simple: The brand wins because doctors trust the system, not because patients are pushed.

DATA LAYER

- no unnecessary patient-identifiable data
- encrypted event IDs
- clinic-level reporting
- consent-based communication
- no direct-to-patient brand retargeting

WHY FIRST MOVER MATTERS

IN AMOXICILLIN-CLAVULANATE, FIRST MOVER ADVANTAGE IS UNUSUALLY STRONG

The first brand to install a responsible-use clinic workflow gets:

- first claim on stewardship infrastructure
- first association with completion and review
- first behavioural dataset around post-prescription leakage
- first clinic habit loop
- first doctor trust advantage
- first opportunity to make older antibiotic promotion look obsolete

Later entrants can copy reminder campaigns. They cannot easily copy first ownership of the clinic workflow.

Once a doctor has a clinic-branded system that helps patients complete prescriptions, avoid substitution, and return when needed, a competing brand must do more than offer another visual aid. It must displace infrastructure. That is harder.

STRATEGIC OPPORTUNITY & CTA

The commercial question for brand teams is therefore straightforward: Do you want to continue competing only for prescription recall, or do you want to become the brand associated with responsible antibiotic control inside real clinic practice?

EMAIL: AMIT@INDITECH.CO.IN

WEBSITE: WWW.INDITECH.CO.IN

One gap in levocetirizine remains commercially unowned: how clinics retain control after the oral-antihistamine decision is made

This is where brand choice is either reinforced - or repeatedly reopened through substitution, recurrence, and habit drift.

The next competitive advantage will come from embedding the brand into a clinic workflow that helps doctors:

- guide appropriate oral-antihistamine use,
- structure recurrence review,
- and retain continuity across repeat allergy episodes.

INDITECH HEALTH SOLUTIONS

PUBLICATION NO. 2026 05 90

www.inditech.co.in